Gilead Sciences (GILD) Tops Q4 EPS by 32c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St set to open higher after inflation data, earnings boost
- Oil prices rise after ship attacks, US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Gilead (GILD) Needs Impactful M&A for the Next Leg of Growth - Piper Jaffray
February 3, 2016 9:11 AM ESTPiper Jaffray analyst, Joshua Schimmer, is hoping to see an impactful acquisition to propel Gilead Sciences (NASDAQ: GILD) into its next leg of growth. However, at 7x next year's eps, the stock may have hit bottom.
GILD reported a very strong 4Q15, bolstered by strong HCV sales in Japan, partially offset by limited VA HCV starts in the quarter. The company guided to flat/slightly down product sales in 2016 and a significant uptick in R&D (+12%-23%) and SG&A (+2%-12%). The company is increasing its dividend... More
Standpoint Research Starts Gilead Sciences (GILD) at Buy
February 3, 2016 8:22 AM ESTStandpoint Research initiated coverage on Gilead Sciences (NASDAQ: GILD) with a Buy rating and a price target of $110.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $82.71 yesterday.
... MoreJapanese Hep C Boosts Gilead Sciences (GILD) in the Qtr - Baird
February 3, 2016 7:20 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and $135 price target on Gilead Sciences (NASDAQ: GILD) following Q4 results which beat on Japanese Hep C.
Skorney commented, "Gilead delivered another top- and bottom-line beat, driven by Japanese Hep C sales. We... More
Gilead's (GILD) Increased Unit Sales Tempered By Lower Prices - Oppenheimer
February 3, 2016 7:11 AM ESTOppenheimer analyst, Wendy Lam, trimmed her price target on Gilead Sciences (NASDAQ: GILD) as the increasing volume of Harvoni will be offset by reductions in price. One bright note was the strong start to HIV as Genvoya generated $44B in sales. PT is cut to $120 from $124 but maintaining the Outperform rating.
GILD reported 4Q15 revenue of $8.5B and non-GAAP EPS of $3.32, topping Street consensus estimates of $8.2B and $3.00. However, GILD's 2016 guidance on net product sales of... More
Gilead Sciences (GILD) Declares $0.43 Quarterly Dividend; Adds $12B to Stock Buyback Plan
February 2, 2016 4:03 PM ESTGilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.43 per share, or $1.72 annualized.
The dividend will be payable on March 30, 2016, to stockholders of record on March 16, 2016, with an ex-dividend date of March 14, 2016.
The annual yield on the dividend is 2.1 percent.
In addition the Board authorized an increase of 4 cents (ten percent) in the companys quarterly dividend program,... More
Intercept Pharma (ICPT) on Watch Following Rumors Out of UK
February 2, 2016 9:54 AM ESTIntercept Pharma (NASDAQ: ICPT) shares were on watch Tuesday after M&A rumors resurfaced in Daily Mail. The rumor suggested the company could auction itself off given interest from major pharma companies Shire plc (NASDAQ: SHPG), Gilead Sciences (NASDAQ: GILD), Bristol-Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE).
... More